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Purpose: Gadofosveset is a Gd-based contrast agent used for magnetic resonance imaging (MRI). Gadolinium kinetic
distribution models are implemented in T1-weighted dynamic contrast-enhanced perfusion MRI for characterization
of lesion sites in the body. Physiology changes in a disease state potentially can influence the pharmacokinetics of
drugs and to this respect modify the distribution properties of contrast agents. This work focuses on the in silico
modelling of pharmacokinetic properties of gadofosveset in different population groups through the application of
physiologically-based pharmacokinetic models (PBPK) embedded in Simcyp® population pharmacokinetics platform.
Methods: Physicochemical and pharmacokinetic properties of gadofosveset were introduced into Simcyp® simulator
platform and a min-PBPK model was applied. In silico clinical trials were generated simulating the administration of
the recommended dose for the contrast agent (i.v., 30 mg/kg) in population cohorts of healthy volunteers, obese,
renal and liver impairment, and in a generated virtual oncology population. Results were evaluated regarding basic
pharmacokinetic parameters of Cmax, AUC and systemic CL and differences were assessed through ANOVA and
estimation of ratio of geometric mean between healthy volunteers and the other population groups.
Results: Simcyp® predicted a mean Cmax = 551.60 mg/l, a mean AUC = 4079.12 mg/L*h and a mean systemic
CL = 0.56 L/h for the virtual population of healthy volunteers. Obese population showed a modulation in Cmax and
CL, attributed to increased administered dose. In renal and liver impairment cohorts a significant modulation in
Cmax, AUC and CL of gadofosveset is predicted. Oncology population exhibited statistical significant differences
regarding AUC when compared with healthy volunteers.
Conclusions: This work employed Simcyp® population pharmacokinetics platform in order to compute gadofosveset’s
pharmacokinetic profiles through PBPK models and in silico clinical trials and evaluate possible differences between
population groups. The approach showed promising results that could provide new insights regarding administration of
contrast agents in special population cohorts. In silico pharmacokinetics could further be used for evaluating of possible
toxicity, interpretation of MRI PK image maps and development of novel contrast agents.
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Gadofosveset trisodium (Vasovist®, Ablavar®, Figure 1A)
is a Gd-based contrast agent (GBCA) used in dynamic-
contrast enhancement magnetic resonance image (DCE-
MRI). The mechanism of action of GBCAs in DCE-MRI
relies in the alteration of relaxation times of atoms* Correspondence: marspan@ics.forth.gr; kmarias@ics.forth.gr
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reproduction in any medium, provided the origwithin body tissues due to the paramagnetic behavior of
Gd and the interaction with nearby hydrogen nuclei
which shortens the longitudinal relaxation (T1) times of
water in the local tissue and increases signal intensity on
T1-weighted images (Gossuin et al. 2010). In DCE-MRI,
depending on the distribution rate of the contrast agent
in a specific organ lesion, several essential information
are gathered such as transfer constant rates (ktrans, kep),
extravascular extracellular space volume per unit volume
of tissue (ve), blood plasma volume per unit volume ofThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
Figure 1 Contrast agent and PBPK model used in this study. (A) Chemical structure of gadofosveset. (B) Graphical representation of the
min-PBPK model applied for gadofosveset from the Simcyp® simulator platform with hepatic clearance set to zero (x) and elimination occurring
only from the systemic compartment through kidneys.
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by artery (arterial input function, AIF) (Koh et al. 2011;
Tofts et al. 1999). A main characteristic of gadofosveset
is the reversible binding to endogenous serum albumin
with a moderate affinity (Kd = 85 μΜ) which leads in a
prolonged vascular residence time compared to non-
protein binding contrast agents and also facilitates high
resolution in arterial and venus images (Caravan et al.
2002). Gadofosveset, as DCE-MRI contrast agent, has
been applied for diagnosis and characterization of brain
and rectal tumors associating DCE-MRI calculated param-
eters with microvascularity and in particular, with angio-
genesis related leakage for tumorous areas (Lambregts
et al. 2013; Puig et al. 2013). The contrast agent also be-
longs to the category of blood-pool contrast agents for
magnetic resonance angiography (MRA) in cases of per-
ipheral vascular disease (PVD) or aortoiliac occlusive dis-
ease (AIOD) (Goyen 2008). As a DCE-MRI contrast agent,
gadofosveset is available in US with approval from FDA
(FDA 2011), whereas in EU, the European Commissionissued a decision (EMA/854517/2011) to withdraw the
marketing authorization for gadofosveset based on com-
mercial reasons from marketing authorization holder
(MAH) (EMA 2011).
Regarding GBCA pharmacokinetics, after intravenous
(i.v.) administration, GBCAs distribute in the blood and
into extravascular-extracellular space. GBCAs follow a
bi-compartment pharmacokinetic profile in the body
with a distinct distribution and elimination phase (Aime
and Caravan 2009). Gadofosveset, according to summary
of product characteristics in humans, shows a mean dis-
tribution half-life of 0.48 ± 0.11 hours and a mean half-
life of 16.3 ± 2.6 hours in elimination phase which is
associated with albumin binding. The agent doesn’t fol-
low any substantial biotransformation through metabolic
processes and the volume of distribution is estimated ap-
proximately to be 148 ± 16 mL/kg. Gadofosveset is elimi-
nated exclusively through kidneys in the urine with an
estimated renal clearance of 6.57 ± 0.97 mL/h/kg. The
83.5% of an i.v. dose is excreted over 14 days and 94% of
Table 1 Basic physicochemical and pharmacokinetic
properties of gadofosveset that were used in the
Simcyp® simulator platform
Physicochemical properties






Dose (IV) 0.03 mmol/Kg (or 30 mg/kg)
CL (mL/min/kg) 6.57 ± 0.97 ml/h/kg
Vd L/Kg 0.15 ± 0.01 ml/Kg (fu = 15–20%)
Elimination t1/2 18.5 h
Distribution t1/2 0.48 h
Route of elimination Kidneys (94% of urinary excretion
occurs in the first 72 hr)
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small proportion of the dose is recovered in feces (Aime
and Caravan 2009; FDA 2011).
Physiologically-based pharmacokinetic models (PBPK)
represent a well-established approach in order to assess
PK profiles of xenobiotics under various physiological
conditions. PBPK models integrate data by taking into
account drug-dependent and physiological related pa-
rameters (i.e. organ volume, demographics, disease, gen-
etics etc.) as well as, their variation amongst individuals
(Rowland et al. 2011). This approach allows the simula-
tion and prediction of PK parameters of drugs in virtual
populations and provides insights in several essential
pharmacological questions such as PK profiles in special
population groups (Atkinson and Smith 2012; Rostami-
Hodjegan 2012). Simcyp® population-based simulator is
a software for mechanistic PBPK modeling and simula-
tion of pharmacokinetics and/or pharmacodynamics in
virtual populations (www.simcyp.com). Apart of other
advantages, the platform gives also the availability of
conducting in silico clinical trials in different population
groups based on disease state (Jamei et al. 2013).
Pharmacokinetic clinical data for administration of
gadofosveset in special population groups are currently
limited. Generally, renal impairment and in some cases
liver deficiency, have been studied for possible modula-
tion of GBCAs kinetics (Davies et al. 2002; Swan et al.
1999). Especially for renal impairment it is well-known
that administration of GBCA for DCE-MRI is avoided
due to the accumulation of Gd in the body and the high
risk of presenting nephrogenic systemic fibrosis (NSF)
(Abraham and Thakral 2008; Hasebroock and Serkova
2009; Grobner and Prischl 2007). Till today there are
some case reports regarding NSF toxicity after adminis-
tration of GBCAs in patients with several comorbidities
and some considerations regarding possible toxicity in
cancer patients (Gandhi et al. 2012; Launay-Vacher et al.
2007; Badero et al. 2008; Grebe et al. 2008). Furthermore,
recently published works focus on physiology characteris-
tics and their impact on estimation of DCE-MRI parame-
ters (Just et al. 2011; Lavini and Verhoeff 2010). All the
above are posing the question whether significant modula-
tions of pharmacokinetics should be expected after admin-
istration of gadofosveset in special populations such as
obese or cancer patients and also if they should be taken
into consideration in the clinical level regarding toxicity or
DCE-MRI parameter estimation.
The aim of this work was to assess, through PBPK
models and in silico clinical trials, the PK profiles of
gadofosveset in different populations in which the
contrast agent could potentially be used for DCE-MRI
studies and evaluate possible differences among these co-
horts. To this respect, the use of in silico clinical trials ap-
proach was implemented through the Simcyp® populationpharmacokinetics platform. Best to our knowledge for
gadofosveset, this is the first attempt to calculate the PK
profiles through the application of PBPK modeling and
in silico clinical trials.
Methods
Gadofosveset physicochemical and PK properties (Table 1)
were obtained from Drugbank (Wishart et al. 2008) and
were used to generate a compound in the Simcyp® simu-
lator platform (Simcyp. V13 Simcyp Ltd, Sheffield, UK).
In addition to these properties the albumin-binding
(Kd = 85 μΜ) was introduced with simulator’s calculator
to estimate that fraction unbound (fu) in plasma to be
0.11. Following the input of contrast-agent parameters,
Simcyp’s min-PBPK model was applied in order to simu-
late the bi-compartmental behavior of gadofosveset. In this
min-PBPK approach all organs and compartments (except
liver and portal vein) are lumped and two more compart-
ments are introduced, one representing the blood pool
and a second, single adjusted compartment (Vsac), which
in this case represented the extravascular-extracellular
space (Figure 1B). GBCAs eliminate through kidneys and
any modulation of kidney function is related with accumu-
lation of Gd in the body and possible toxicity (Abraham
and Thakral 2008; Amet and Deray 2012; Hasebroock and
Serkova 2009). To this respect, elimination settings for
organ metabolic clearance adjusted to zero for all organs
and elimination set to be occurred exclusively from the
systemic compartment through kidneys (Figure 1B). In
addition, following the reported value of clearance for
gadofosveset, a typical value of renal clearance for a healthy
male 20–30 years old set to be 0.5 L/h. Through this ap-
proach, simulator set to estimate through its algorithms,
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modulation of renal function due to the disease or physi-
ology changes taking into account the clearance value of a
healthy male 20–30 years old.
The simulated clinical trials carried out in the fol-
lowing virtual population groups of Simcyp’s platform:
i) healthy volunteers, ii) renal impairment with GFR
values between 30–60 iii) renal impairment with GFR
below 30, iv) obese, and v) Liver cirrhosis (types A, B, C).
Also in silico clinical trials were conducted in a virtual on-
cology group generated according to a recently published
work (Cheeti et al. 2013). All simulations run for 10 clinical
trials of 10 subjects in each trial (0.5 females). In order to
assess the prolonged elimination of gadofosveset, the in
silico clinical trials were generated over a time period of
72 hours following the usually administered i.v. dose of the
contrast agent (30 mg/kg).
The obtained results were evaluated in GraphPad
Prism® (v5.01 GraphPad Software Inc.) for possible statis-
tical significant differences through ANOVA using
Dunnet’s test in order to compare all populations with
healthy volunteers, (95% confidence intervals) follow-
ing log-transformation. The ratio of geometric mean
(GMR ± 0.2) for Cmax, AUC and CL between healthy
volunteers (control group) and other population groups
was used to briefly estimate the equivalence of gadofos-
vesest administration between population cohorts.
Results and discussion
The calculated pharmacokinetic parameters of gadofos-
veset are presented in Table 2 and the concentration-
time profiles of the mean values along with the upper
and lower percentile for each population are illustrated
in Figure 2(I-VIII). Pharmacokinetic profiles and parame-
ters seem to differentiate in the other population cohorts
as it is shown in Figure 2(II-VIII) and Table 2. Figure 3
shows the modulation from the ratio of geometric mean of
Cmax, AUC and CL between healthy volunteers and theTable 2 Mean administered doses (total mg) and mean (±SD)
CL (L/h) and fraction of dose excreted in urine (fe) for gadofo
Pharmacokinetic parameter
Population group Dose (mg) Cmax (mg/L)
Healthy volunteers 2212.90 (±385.49) 551,60 (±84.29
Renal impairment GFR 30–60 2104.51 (±453.87) 508.34 (±73.37
Renal impairment GFR < 30 2104.51 (±453.87) 462.46 (±65.38
Obese 2997.52 (±373.76)*** 633.54 (±72.04
Oncology 2228.18 (±478.72) 509.27 (±87.81
Liver cirrhosis type A 2283.12 (±459.26) 443.61 (±65.99
Liver cirrhosis type B 2283.12 (±459.26) 352.75 (±55.22
Liver cirrhosis type C 2283.12 (±459.26) 284.60 (±44.89
*P < 0.05, **P < 0.01, ***P < 0.001 statistical significant differences with control groupother population groups. The elimination of gadofosveset
was in linear correlation to kidney function and GFR for all
population groups and the cumulative amount –or the
fraction of administered dose – of contrast agent excreted
in urine was similar in most cases except in kidney and
liver impairment (Table 2, Figure 4).
The results from population of healthy volunteers
predict a mean Cmax = 551.60 mg/L, a mean AUC =
4079.12 mg*h/L and a systemic CL of 0.56 L/h (or
7.56 L/h/kg) for gadofosveset. Moreover the mean frac-
tion of dose eliminated through kidneys (fe) over a time
period of 72 predicted to be 0.94 (Table 2). The calcu-
lated values for virtual population of healthy volunteers,
mainly CL and fe, are in good correlation with values
from the literature and are presented in Table 3 (FDA
2011; Wishart et al. 2008). Theoretically, taking into ac-
count the protein binding, renal elimination of gadofos-
veset expected to be 0.86 L/h (fu*GFR) whereas the
predicted (0.56 L/h) for healthy volunteers) as well as the
reported (0.49 L/h) values of renal elimination are much
lower. This finding suggests a possible active tubular re-
absorption of the contrast agent but till today there are
no any data available for active transport during elimin-
ation and thus far no transporters have been identified
where the agent could serve as substrate. The only con-
trast agents with active transport are gadobenate dime-
glumin (Gd-BOPTA, MultiHance®) and gadoxetic acid
(Gd-EOB-DTPA, Primovist®) (Pascolo et al. 1999). As a
result, due to the good correlation of in silico data with
reported values (Table 3) this approach through Simcyp®
seems capable to predict the basic pharmacokinetic pro-
file and parameters of gadofosveset compared with re-
ported values and as a result, healthy volunteers served
as control group towards the evaluation of the PK param-
eters in the other population cohorts.
In the two renal impairment populations, the simula-
tions successfully predicted the expected and statistically
significant delayed elimination and accumulation in thepredicted values of Cmax (mg/L), AUC (mg*L/h), systemic
sveset in simulated populations
AUC (mg/L*h) CL(L/h) fe
) 4079.12 (±822.39) 0,56 (±0.11) 0.94 (±0.04)
) 7364.89 (±931.76)*** 0.29 (±0.05)*** 0.68 (±0.05)***
)*** 8837.03 (±1135.09)*** 0.24 (±0.04)*** 0.42 (±0.05)***
)*** 4122.79 (±769.33) 0.75 (±0.11)*** 0.96 (±0.04)
) 4551.60 (±841.70)* 0.50 (±0.09) 0.90 (±0.06)
)*** 5814.62 (±942.87)*** 0.40 (±0.06)*** 0.74 (±0.03)***
)*** 5557.40 (±798.26)*** 0.41 (±0.06)*** 0.60 (±0.11)***
)*** 4932.06 (±668.71)*** 0.46 (±0.07)** 0.51 (±0.11)***
(healthy volunteers).
Figure 2 Semi-log plots of systemic concentration in plasma over time of gadofosveset in the simulated populations groups. (I) Healthy
volunteers, (II) Renal impairment (GFR30-60) (III) Renal impairment (GFR < 30), (IV) Obese, (V) Oncology, (VI) Liver cirrhosis type A, (VII) Liver cirrhosis
type B, (VIII) Liver cirrhosis type C.
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(P < 0.001) (Figure 2I-III). The results from Simcyp® for
administration of gadofosveset in renal impairment pre-
dict a slight modulation in Cmax whereas a 1.8 and 2.2
fold increase in AUC with the respective decrease in CL
was predicted for the two cohorts of renal deficiency
(Figure 3) which were in good correlation with known
data (Table 3). The accumulation of gadofosveset in the
body was also associated with disease severity and the
decrease in GFR values (Figures 2II, III and 4). These re-
sults seem to correlate with the known impact of kidney
function in GBCA elimination and increased risk of tox-
icity and potentially could be used to further explain
cases of acute renal failure and Gd-toxicity (Bhaskaran
et al. 2010).
For obese population (Figure 2IV), a statistically sig-
nificant increase in Cmax and CL (P < 0.001) was pre-
dicted without modulation in calculated AUC (Figure 3).
This difference can be attributed to the higher total ad-
ministered dose of the contrast-agent based on the bodyweight (Table 2). The fraction of the dose eliminated in
obese people seems to remain similar (fe = 0.96) with
healthy volunteers of normal body weight but the in-
creased total administered dose leads in a higher cumu-
lative amount of gadofosveset that is calculated to be
excreted in the urine (Table 2, Figure 4B). Obese popula-
tion was applied due to the administration of GBCA
based on body weight and in an effort to assess the pos-
sible impact on gadofosveset pharmacokinetic parame-
ters. Previously published studies with PBPK models
have shown that for several pharmacokinetic parameters,
especially for clearance, variations due to increased body
weight should be expected (Ghobadi et al. 2011). The in-
creased exposure in gadolinium potentially could be
related with toxicity and also regarding the DCE-MRI
could lead in an increased signal intensity.
Regarding the oncology group, a statistical significant
difference in AUC is estimated (P < 0.05) whereas modu-
lation in Cmax and CL is not predicted compared with the
population of healthy volunteers (Figure 3 and Table 2).
Figure 3 Geometric mean ratio (GMR ± 95% upper or lower limit) of Cmax, AUC amd CL values for gadofosveset in the simulated
population groups. Dashed vertical lines represent values of 0.8 and 1.2 below and above GMR between healthy volunteers and the other
simulated populations.
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Figure 4 Renal elimination and urinary recovery of gadofosveset. (A) Linear correlation of GFR and systemic clearance of gadofosveset in
simulated individuals in all population groups. (B) Calculated mean urinary recovey of gadofosveset in different population groups over a time
period of 72 h.
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eral physiology changes that are observed in cancer
patients without taking into account possible organ
dysfunction, especially in kidneys, with the potential
impact on contrast agent PKs and moreover in present-
ing adverse reactions (Amet and Deray 2012; Launay-
Vacher et al. 2007). In addition, although the clinical
impact in DCE-MRI of the modulation of AUC be-
tween healthy volunteers and cancer patients remains
to be further addressed, it is expected to contribute in theTable 3 Comparison of the pharmacokinetic parameters
that were predicted through Simcyp® simulator with the
values available from the literature (FDA and Drugbank)
for populations of healthy volunteers and renal impairment
patients




Cmax (mg/L) (mean ± SD) 551.60 (±84,29) 419.6 (±39.04)
C t=1h (mg/L) (mean ± SD) 256.17 (±35.41) 234.21 (±29.27)
fu 0.11 0.12–0.20
CL (mL/h/kg) (mean ± SD) 7.56 (±1.46) 6.57 (±0.97)
fe (72 h) 0.94 0.94
AUC fold increase in moderate
renal impairment
1.8 1.75
AUC fold increase in severe
renal impairment
2.2 2.25interpretation of the imaging results (e.g. role of PK in
tumor characterization).
Populations of liver cirrhosis (types A, B, C), exhibited
a decreased Cmax concentration compared with other
groups and a similar trend in c-t profiles with those of
renal impairment cohorts (Figure 2VI-VIII, Table 2). In
addition, results from simulations calculate a statistical
significant increase in AUC and decrease in CL in these
cohorts. Furthermore, modulation in Cmax, AUC and
CL seem to follow disease severity and progression
(Figure 3). These findings could be attributed with the
changes in physiology observed and taken into consider-
ation during simulations in liver deficiency that lead in
decreased renal function and hepatorenal syndrome (Lata
2012). As a result, administration of gadofosveset for
DCE-MRI in patients with liver cirrhosis could take into
consideration the possible hepatorenal syndrome in order
to prevent potential toxicity. Also a modulation from the
expected values, mainly in AIF, could be expected in
DCE-MRI setting. Comparing these findings with FDA’s
SPC though, pharmacokinetics and plasma protein bind-
ing of gadofosveset have not reported till today to be sig-
nificantly influenced by moderate hepatic impairment
and the only value that is influenced is the fecal elimin-
ation of the contrast agent which is reduced in hepatic
impaired subjects (FDA 2011).
Summarizing the above observations, application of
Simcyp® simulator platform on gadofosveset and the
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in estimating the pharmacokinetic properties and pro-
files of gadofosveset and identify possible differences
between several population groups. PBPK models and
simulators for in silico clinical trials such as Simcyp®
can be promising in providing new insights regarding
the pharmacokinetic behavior of contrast agents in the
body and the variability in the estimated MRI values,
especially in disease population groups where clinical
trials cannot easily been conducted. Thus far, Simcyp®
simulator platform has been applied in predicting PK
profiles of drugs in special population groups such as
obese, renal deficiency, liver impairment and rheumatoid
arthritis with good correlation between disease model
and clinical data (Johnson et al. 2010; Machavaram et al.
2013; Rowland Yeo et al. 2011; Ghobadi et al. 2011).
Although, Simcyp® platform represents a “bottom-up”
PBPK approach where in vitro data are extrapolated
to possible in vivo results, in this study, the in silico
clinical trials implementations were based on known
in vivo parameters in an effort to combine clinical data to
“bottom-up” PBPK models (Tsamandouras et al. 2013).
The application of PBPK models and the results from in
silico clinical trials can also be applied towards the develop-
ment of novel GBCAs or for further developing/improving
models for MRI PK analysis (Huang and Tsourkas 2013;
Lim et al. 2012; Brochot et al. 2006; Bui et al. 2010).
Overall, the proposed application of in silico clinical
trials for gadofosveset, represent a novel approach for
the estimation of PK parameters and population variabil-
ity regarding GBCAs. The observations from the in silico
population analysis revealed several new aspects that can
possibly be evaluated with clinical observations for gado-
fosveset which till today are limited. Moreover, PBPK
models can provide tools where differences in acquired
MRI images could be attributed in physiology character-
istics and not strictly to an observed lesion which poten-
tially would provide new insights for MRI image analysis
regarding GBCAs pharmacokinetics modeling. The ex-
ploitation of the results and correlation with clinical
findings, along with systems biology tools and interfaces
integrating patients profiles could further empower deci-
sion making tools in predicting the Gd concentration
variability in patients and therefore assisting the clinician
to better explain interesting findings in PK-derived dis-
ease related biomarkers (Spanakis et al. 2013).
Conclusion
The PBPK-based in silico analysis results showed a good
correlation with the literature related to gadofosveset’s
pharmacokinetic parameters. Differences between healthy
volunteers and specific population groups were observed
and discussed regarding the potential impact in DCE-MRI
and toxicity. Prospectively, this approach based on in silicopopulations has the potential to shed light in the under-
standing MRI PK parameters variability observed in clinical
practice, lead to more robust MRI biomarkers by factoring
out population-dependent PK variability and enhance drug
development processes for novel contrast agents. Towards
this goal, we aim to extend our work in coupling the appli-
cation of PBPK models with in silico clinical trials for opti-
mizing the clinical value of MRI biomarkers.
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